FDA Accepts NDA for Brain Cancer Imaging Agent TLX101-Px (Pixclara®), Sets September PDUFA Date
Summary
The FDA has accepted Telix's resubmitted New Drug Application for TLX101-Px (Pixclara®), an imaging agent for brain cancer, and set a PDUFA goal date of September 11, 2026.
Key Events
-
NDA Accepted for TLX101-Px (Pixclara®)
The FDA has accepted Telix's resubmitted New Drug Application for TLX101-Px, an investigational PET agent for imaging glioma (brain cancer).
-
PDUFA Goal Date Set
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for potential approval.
-
Addresses Unmet Medical Need
TLX101-Px is intended to characterize recurrent or progressive glioma, a significant unmet medical need, and holds Orphan Drug and Fast Track designations.
-
Potential Upside to Guidance
Telix's current FY 2026 financial guidance does not include any revenue contribution from TLX101-Px, suggesting potential upside upon approval.
Analysis
The FDA's acceptance of the New Drug Application (NDA) for TLX101-Px (Pixclara®) is a significant de-risking event for Telix Pharmaceuticals. This investigational PET agent, designed for imaging glioma (brain cancer), addresses a critical unmet medical need and has previously received Orphan Drug and Fast Track designations. The assignment of a PDUFA goal date of September 11, 2026, provides a clear timeline for a potential regulatory decision, which could unlock a new revenue stream. Notably, Telix's current FY 2026 financial guidance does not factor in any revenue from TLX101-Px, indicating that a potential approval and subsequent commercialization could represent significant upside to existing expectations.
At the time of this filing, TLX was trading at $10.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $6.28 to $20.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.